New antiepileptic drug safety information is not transmitted systematically and accepted by U.S. neurologists  by Bell, Sarah G. et al.
Epilepsy & Behavior 29 (2013) 36–40
Contents lists available at ScienceDirect
Epilepsy & Behavior
j ourna l homepage: www.e lsev ie r .com/ locate /yebehNew antiepileptic drug safety information is not transmitted
systematically and accepted by U.S. neurologistsSarah G. Bell a, Martha Matsumoto a, Susan J. Shaw b, Jason Brandt c, Gregory L. Krauss a,⁎
a Johns Hopkins University, Department of Neurology, 600 N. Wolfe St., Meyer 2-147, Baltimore, MD 21287, USA
b University of Southern California, Keck School of Medicine, Department of Neurology, Rancho Los Amigo National Rehabilitation Center, 7601 E. Imperial Highway, HB 145, Downey,
CA 90242, USA
c Johns Hopkins University, Division of Medical Psychology, 600 N. Wolfe St., Meyer 218, Baltimore, MD 21287, USA⁎ Corresponding author at: 600 N.Wolfe St., Meyer 2-1
Fax: +1 410 955 0751.
E-mail address: gkrauss@jhmi.edu (G.L. Krauss).
1525-5050
http://dx.doi.org/10.1016/j.yebeh.2013.06.008
© 2013 The Authors. Published by Elsevier Ia b s t r a c ta r t i c l e i n f oArticle history:
Received 1 May 2013
Revised 3 June 2013
Accepted 8 June 2013
Available online 7 August 2013
Keywords:
Antiepileptic drugs
Patient safety
Methods of education
Error in medicine
Professional conduct and ethicsWe surveyed U.S. neurologists in order to evaluate their knowledge of, and sources for, recent FDA safety warn-
ings regarding antiepileptic drugs (AEDs) and whether they incorporate this information into their practices.
Survey respondents (N = 505)were predominantly board-certiﬁed American Academy of Neurologymembers.
Approximately 20% of respondent neurologists were not aware of warnings about four drug safety risks:
suicidality with newer AEDs, increased birth defect risks from in utero divalproex exposure, impaired cognitive
development from in utero divalproex exposure, and the requirement of haplotype screening in patients of Asian
descent starting carbamazepine. Most respondents were aware of a recommendation for haplotype screening,
yet did not routinely perform the safety screening, and 18 reported patients that had hypersensitivity reactions
to carbamazepine. Respondents learned about drug safety risks from varied sources; only notiﬁcations from
specialty organizations were associated with accurate knowledge of drug safety warnings. Most surveyed neu-
rologists would prefer implementing “a formal warning process via specialty organizations” with e-mails of
updated product insert warnings.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Neurologists need up-to-date information on the safety of widely
used medications to care for their patients effectively. The safety
warnings of the FDA, however, are not systematically transmitted to
neurologistswho, as a result, may not become aware ofmajor drug safe-
ty risks. The FDA reports these risks in “Drug Safety Communications”
and “MedWatch Alert” e-mails, but these are only directly transmitted
to neurologists registered for notiﬁcations. Physician specialty organiza-
tions, including the American Academy of Neurology (AAN), occasional-
ly receive e-mail warnings of safety risks from the FDA, whichmay then
be passed along to members. The FDA also requires that drug manufac-
turers update product inserts and highlight particularly severe or un-
usual drug safety risks in “black box” warnings and “Dear Health Care
Provider” letters [1,2]. Many neurologists learn of drug safety risks
from published articles and continuing medical education (CME). It re-
mains unclear, however, whether safety data are communicated to neu-
rologists effectively and whether physicians implement recommended47, Baltimore, MD 21287, USA.
nc. Open access under CC BY-NC-ND lidrug safety screening into their practices. Previous studies, for example,
show that physicians are often aware of updated drug safety informa-
tion but may not carry out recommended practices [3–5].
Four new safety risks for antiepileptic drugs (AEDs) have been re-
cently identiﬁed: increased suicidal thoughts or behavior with newer
AEDs [6], high risks for birth defects [7] and cognitive impairment [8]
in the offspring ofmothers receiving divalproex, and risks for hypersen-
sitivity reactions in patients of Asian descent starting carbamazepine
[9]. The empirical basis and causative relationships underlying some
of the FDAwarnings, particularly regarding suicidality, are controversial
[10]. However, we believe it is important for neurologists to be aware of
major drug safety warnings in order to incorporate appropriate safety
screening procedures and patient counseling into their practices. We
surveyedU.S. neurologists to determinewhether theywere aware of re-
cent AED safety warnings, their sources of drug safety information, and
whether they incorporate this safety information into their practices.
This information may help identify optimal methods for imparting im-
portant safety updates to neurologists.
2. Methods
2.1. Standard protocol approvals and patient consents
This survey study meets the criteria for research exempt from IRB
monitoring under Exemption 45 CFR 46.101(b)(2).cense.
Table 1
Demographics of neurologist survey respondents compared to active AAN members:
Survey respondents' demographics were similar to active AAN members, but a higher
proportion of respondents were board-certiﬁed and were in academic practice.
Survey neurologists Active AAN neurologists
Total respondents 505
Mean age (range) (years) 48.9 (29–77) 53.3
Work settings (%)
Academic hospital/clinic 39.8 27.1a
Solo practice 17.6 22.9
Group practice 31.9 37.4b
Community hospital 6.7
Research 1.2
Other 2.8 7.4c
Board-certiﬁed (%) 96.4 76
Gender
Male 66.5 76.1
Female 33.5 23.9
a The AAN membership practice demographics describe this as “University-Based
Group” and “Government Hospital or Clinic.”
b This represents U.S. neurologists in the AAN membership practice demographics
who fell into the “Neurology Group” or the “Multispecialty Group.”
c This represents U.S. neurologists in the AAN membership practice demographics
who fell into “Staff-Model HMO” or “Other Public or Private Hospital or Clinic.”
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A master list of active members of the American Academy of
Neurology (AAN) was stratiﬁed by state and systematically sampled.
Surveys were transmitted to 4627 U.S. neurologists by three e-mail
requests. The survey was conducted using “SurveyGizmo,” an Internet-
based survey tool. Neurologistswere asked to answer questionswithout
consulting outside sources.
2.3. Survey questions
Survey questions concerned the following four recently identiﬁed
safety risks: (1) A high risk for hypersensitivity reactions (e.g., Stevens–
Johnson syndrome and toxic epidermal necrolysis) with carbamazepine
use has been associated with the HLA-B*1502 haplotype marker, which
is more common in patients of Asian descent. The FDA recommends
haplotype screening for patients of Asian descent before initiating
carbamazepine therapy [11]. (2) The FDA identiﬁed a doubling of risk
for “suicidality” in patients beginning treatmentwith 11 AEDs, with sui-
cidal ideation risk increasing from 2.4 to 4.3 per 1000 patients. Though
controversial among neurologists, the FDA recommends warning
and monitoring patients who are prescribed these AEDs. (3) Recent
studies have shown an increase in the previously reported risks for
malformations in the offspring of women treated with divalproex,
with a risk of approximately 10.7% at the time of the survey [7]. (4) A
major longitudinal study recently identiﬁed increased risk for cognitive
limitations in children after exposure in utero to divalproex, with a de-
crease of 6 to 9 IQ points compared to the offspring ofmothers on one of
three alternative AEDs during pregnancy [8]. Only preliminary ﬁndings
are reported in the drug product insert [12], and this was used as a test
of knowledge of an evolving safety risk. We also included a control
question; neurologists were asked whether they knew that lacosamide
did not have “black box” safety warnings. Neurologists were also asked
to rank ﬁve methods of distributing drug safety information from most
effective to least effective. The complete list of survey questions and
neurologist responses can be found in the supplementary addendum.
2.4. Statistical analysis
Respondents were scored on their knowledge of the exact level of
risk cited by the FDA and on their knowledge of the existence of a sig-
niﬁcantly increased risk for the four new drug safety questions and
the lacosamide control question. Knowledge of safety risks in neurol-
ogists who did and did not use each source was compared using a
t-test. Additionally, chi-squared tests or ANOVA was used to test for
dependence between demographics, practice characteristics, answers
to individual questions, and use of each source of information.
3. Results
3.1. Characteristics of survey respondents
Six hundred ﬁve (13.1%) of the 4627 survey recipients completed
and returned the survey within six weeks. One hundred respondents
reported that they did not care for patients with epilepsy; responses
from the remaining 505 were analyzed. Responses were received
from all 50 states and the District of Columbia. The backgrounds of
respondents were similar to national AAN membership: one-half
(49.5%) were in solo or group practice, 66.5% were male, mean age
was 48.9 years (range: 29–77), and survey respondents were in prac-
tice an average of 22.4 years (range: 3–52) [13]. The majority (54.0%)
of survey respondents treat at least 100 patients with epilepsy each
year. Compared to all AAN members, a slightly larger proportion of
respondents had academic or government-based practices (27.1%
AAN members; 39.8% survey respondents) and had board certiﬁca-
tion (76%; 96.4%) [13] (Table 1).3.2. Sources for drug safety information
Neurologists reported receiving drug safety information from
multiple sources. The most common sources were the following: no-
tiﬁcations from specialty organizations (67.1%), published literature
(67.1%), colleague and/or peer (53.1%), and CME or other educational
programs (52.9%) (Fig. 1). Respondent neurologists in academic and
private clinical practices usedmany of the same sources of drug safety
information. Private practice neurologists, however, were more likely
to acquire their knowledge from pharmaceutical representatives
(54.8% private, 23.4% academic), while academic neurologists were
more likely to use published literature and colleagues/peers as sources
(59.2% private, 75.1% academic).
3.3. Drug safety survey responses (Table 2)
3.3.1. FDA recommendation to perform haplotype screening prior to
initiating carbamazepine therapy in patients with Asian heritage
Seventy percent of respondents reported that they were aware
of this 2007 FDA recommendation. While 147 neurologists (29.1%)
reported initiating carbamazepine treatment in patients of Asian de-
scent since the warning, only 33 of them (22.5%) said they performed
haplotype screening. Eighteen neurologists reported that their pa-
tients of Asian descent had developed carbamazepine-related hyper-
sensitivity reactions during this time period.
3.3.2. Suicidal ideation with newer AEDs
Of the respondents, 80.6%were aware of the FDAwarning regarding
suicidal thoughts; 70.1% reported counseling patients on this risk in the
three years since the safety notiﬁcation. Only 60.2% of respondents cor-
rectly identiﬁed the risk as 4.3 per 1000 (Fig. 2). Many neurologists
commented that the FDA's ﬁndings and recommendations are contro-
versial and that knowing the exact risk of “suicidality” (itself a nebulous
concept) is not essential to good clinical care.
3.3.3. Increased risks for birth defects with divalproex exposure
Only 33.5% of respondents were aware of the recently identiﬁed
increased risk of birth defects in the offspring of mothers treated
with divalproex. Many noted that it may be sufﬁcient for them to
be aware of an increased risk for birth defects but not of this speciﬁc
risk. Nearly all (93.3%) respondents reported counseling women who
were planning pregnancies on birth defect risks with divalproex
(Table 2).
Fig. 1. In general, what is/are your main source(s) for drug safety information? Each bar represents the percentage of respondent neurologists who answered that they did use the
source. Many neurologists reported having several drug safety information sources.
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The risk of lowered IQ in children with in utero divalproex expo-
sure was recognized by approximately one-half of the respondent
neurologists (48.9%), while 16.9% were not aware of any risk for
decreased IQs (Table 2). The remaining one-third of neurologists
(30.7%) thought that “cognitive and development risks in offspring
exposed to divalproex in utero has not been established.” The current
divalproex product insert does not include this speciﬁc risk but notes
that “there have been reports of developmental delay, autism and/or
autism spectrum disorder in the offspring of women exposed to
valproate during pregnancy.”
3.3.5. No “black box” warnings for lacosamide
Seventy-three percent of respondents correctly answered the con-
trol question and recognized that there was no “black box” warning
for lacosamide (Table 2).
3.4. U.S. neurologists' overall knowledge of drug safety warnings
Of the respondents, 73.9% knew of the increased risks associated
with AEDs, as judged by their recognition of at least 4 of 5 safety issues
queried. However, those who recognized speciﬁc levels of drug risks,Table 2
Neurologists' general and speciﬁc knowledge of ﬁve safety risks for AEDs: approximately
1/5 of neurologists did not recognize general safety risks for the drugs; knowledge of
speciﬁc levels of risks for AEDs varied widely (33 to 74%).
Awareness of
increased riska
N (%) correct
Knowledge of
exact level of riskb
N (%) correct
Hypersensitivity reactions in Asian
patients
410 (81.2%) 373 (73.9%)
Suicidal ideation with newer AEDs 407 (80.6%) 304 (60.2%)
Congenital malformations with
divalproex
399 (79.0%) 169 (33.5%)
Safety risks for lacosamide 368 (72.9%) 368 (72.9%)
IQ changes with divalproex 420 (83.2%) 247 (48.9%)
Total knowledge scores
(for the previous 5 questions)
General awareness
of riska
N (%) correct
Knowledge of
exact level of riskb
N (%) correct
0–1 questions correct 7 (1.4%) 49 (9.7%)
2–3 questions correct 125 (24.8%) 308 (61.0%)
4–5 questions correct 373 (73.9%) 148 (29.3%)
a Did the neurologist identify whether a safety risk existed or not?
b Did the neurologist select the exact level of the increased risk?such as rate of birth malformation with divalproex, were fewer: only
29.3% recognized speciﬁc drug risks for at least 4 of the 5 items que-
ried, and only 6.7% knew all ﬁve.
Only one source of information, notiﬁcations from specialty organi-
zations, was associated with increased speciﬁc knowledge and general
recognition of drug safety risks (speciﬁc knowledge: t(333) = 2.53,
p = 0.012; general recognition: t(321) = 3.33, p = 0.001).
Respondents' practice type, region of practice, years in practice,
and age were not associated with their knowledge of drug safety
issues. The number of patients with epilepsy treated each year
was associated with a modest increase in knowledge of drug safety is-
sues (speciﬁc knowledge: rs = 0.14, p = 0.002; general recognition:
rs = 0.17, p b 0.001).
3.5. Neurologists' preferences for methods to receive updated drug safety
information
Most neurologists prefer to receive safety information from struc-
tured, easily obtained sources. A large number endorsed the creation
of “a formal warning process via specialty organizations” (n = 190)
or e-mails with “updated product insert warnings to specialists in
that ﬁeld” (n = 176). Another 101 neurologists thought that phar-
maceutical companies should be required to “notify physicians of all
major safety updates on product inserts, not just the very serious
‘black box’ warnings.” Few respondents (n = 24) prefer to “continue
the current systemunchanged,” and even fewer (n = 14) prefer relying
on safety information from FDA websites.
4. Discussion
The U.S. neurologists in the survey received drug safety warnings
from multiple sources; however, safety information was not system-
atically delivered, and approximately one-ﬁfth of survey respondents
(17–27% across the ﬁve safety issues) were unaware of recently
reported safety risks with AEDs. Neurologists who treated large num-
bers of patients with epilepsy had an increased knowledge of drug
safety risks compared to other neurologists, though geographic distri-
bution, years in practice, board certiﬁcation, and age were not associ-
atedwith increased knowledge. The onlymethod of safety notiﬁcation
thatwas associatedwith an increased knowledge of drug riskswas no-
tiﬁcations from specialty organizations.
Many neurologists said that they disagreed with the signiﬁcance of
several of the FDAwarnings. For example, many felt that the FDA's ev-
idence for increased risk of suicidality with AEDs was ﬂawed, did not
Fig. 2. Neurologists' estimate of risk for suicidality with newer AEDs. Eighty percent of respondent neurologists recognized an increased risk associated with newer AEDs, and 60%
knew of the speciﬁc risk of 4.3 per 1000. Nineteen percent did not recognize an increase compared to a background risk of 2.4 per 1000.
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necessarily be included in counseling. In a previous 2008 survey
by Shneker et al. [14], many neurologists thought that the FDA
warning on suicidality risks with AEDs was unclear, and they were
not counseling patients on this risk. Some respondents also felt
that having a general awareness of drug safety risks was sufﬁcient
in making clinical decisions. Many, however, did not recognize the
general levels of risk which would be necessary to assess even contro-
versial safety warnings. For example, knowing that the FDA's reported
risk for suicidality with new AEDs is relatively low (4.3 per 1000) is
helpful in deciding whether to counsel patients on the risk.
The FDA's recommended pharmacogenomic screening to avoid
carbamazepine-associated hypersensitivity reactions did not appear to
be effective—many survey neurologists had recently treated Asian pa-
tients with carbamazepine and yet, despite recognizing an association
between the HLA-B*1502 haplotype and carbamazepine hypersensitiv-
ity reactions, failed to screen their patients for the haplotype; 18 neurol-
ogists reported Asian patients developing hypersensitivity reactions.
This is consistent with previous studies showing that the majority of
physicians eventually become aware of FDA drug safety advisories but
that they often do not carry out the recommended safety screening pro-
cedures [4,5,15]. Physicians, for example, often continue prescribing
contraindicated concurrent medications despite drug safety warnings
[16]. Pharmacogenomic safety screening may have failed for multiple
reasons, including the following: the FDA did not provide technical in-
formation on how to obtain and interpret haplotype testing, specialty
organizations have not endorsed or encouraged testing, and logistical
difﬁculties in obtaining testing while delaying treatment may be a bar-
rier for neurologists. In addition, 30% of respondents were not aware of
a requirement to perform haplotype screening.
The difﬁculty of incorporating new information into neurologists'
practices is not exclusive to AED safety risks. For example, an AAN prac-
tice parameter recommending early epilepsy surgery screening for pa-
tients with medically resistant seizures did not reduce the 17-year
average period of patients' pharmacotherapy before they were referred
for surgery evaluation [17]. It is possible that, similar to AED suicidality
warnings, neurologists disagreed with the practice recommendation.
Our survey showed, though, that neurologists receive medical up-
dates nonsystematically from varied sources, and it is likely that
many neurologists were not aware of the practice recommendation.Electronic medical record (EMR) technology would be ideal for
personalizing safety warnings at point of care; for example, pre-
scribers ordering carbamazepine for Asian patients could be warned
that the patient needs haplotype screening. EpiCare (EPIC), a widely
used electronic medical record tool, automatically warns prescribers
of potentially dangerous drug interactions, but it does not link patient
factors and drug safety warnings, e.g., when women of childbearing
age are prescribed divalproex, it does not warn prescribers of high
malformation risks.
We used an Internet survey to permit adaptive questions; however,
the low yield of 13.1% could select for speciﬁc responses—for example,
physicians more knowledgeable about safety risks (or perhaps less
knowledgeable) might be more likely to respond. In a national survey
on colorectal cancer, a much higher proportion of physicians preferred
mail (90%) than Internet (6%) practice surveys, suggesting that neurol-
ogists might also be best surveyed via mailings [18]. Nonetheless, over
500 U.S. neurologists from all U.S. states and practice types responded,
with relatively uniform patterns of responses. Moreover, the sample
was typical for U.S. board-certiﬁed neurologists and AAN members:
all practice types were represented, with the majority of neurologists
in private practice; neurologists' years in practice ranged from 1 to
52 years. In addition, a sensitivity analysis showed consistent responses
across respondents; practice type, location, and years in practice had
little effect on knowledge of drug safety issues. Another limitation
of the questionnaire was that multiple-choice questions were used,
individual responses could not be explored, and only warnings for
antiepileptic drugs were probed. Overall, survey respondent back-
grounds were typical of board-certiﬁed U.S. neurologists, with the ma-
jority in private practices and a slightly higher proportion of academic
neurologists responding than in the overall AAN membership.
Our ﬁndings raise several important issues on how drug safety
screening could be better communicated and implemented. Many
neurologists received new safety information from the FDA, pub-
lished literature, and product insert updates; however, the sources
of safety information varied considerably among neurologists, and
neurologists noted that there was no systematic delivery of safety in-
formation. Despite using multiple sources, neurologists reported that
drug safety information wasmost effectively transmitted via specialty
organizations. These survey results suggest that it may be helpful for
the FDA to review controversial safety warnings and to implement
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organizations. Neurologists would prefer that FDA safety warnings be
communicated more systematically via e-mail summaries speciﬁc to
their specialties. For pharmacogenomic screening, an FDA risk evalua-
tion and mitigation screening (REMS) program could be implemented
which requires safety screening before prescribed drugs are released
by pharmacies, e.g., the vigabatrin vision safety SHARE program [19].
A risk mitigation program may, however, be difﬁcult to implement for
a small at-risk U.S. population and may be more appropriate for more
frequent, serious drug risks.
5. Conclusion
Previous studies have identiﬁed the absence of a structured, sys-
tematic approach to disseminating important drug safety information
to U.S. health-care providers [2,3]. They have also shown that FDA
drug safety communications are most effective when they are speciﬁc
and repeated and when they provide alternative care options to
providers [2]. Our survey showed that only notiﬁcations from specialty
organizations improved neurologists' knowledge of drug safety risks.
Neurologists in the survey strongly suggested that the current system
of disseminating drug safety warnings be changed. Most frequently,
they expressed a preference for a formal drug safety warning process
directed by specialty organizations.Manywould prefer electronic safety
updates for drugs in their specialty ﬁeld. Whether a revised drug safety
notiﬁcation system could be devised to improve knowledge among the
approximately 20% of neurologists who do not recognize important
safety risks despite reporting exposure to multiple sources for drug in-
formation remains to be determined.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.yebeh.2013.06.008.
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